Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

by Mark Clemons, Michelle Liu, Carol Stober, Gregory Pond, Mashari Jemaan Alzahrani, Michael Ong, Scott Ernst, Christopher Booth, Mihaela Mates, Anil Abraham Joy, Olexiy Aseyev, Phillip Blanchette, Lisa Vandermeer, Megan Tu, Kednapa Thavorn, Dean Fergusson
Published 2021-10-01